CAR--话题@MedSci

#CAR-#

459篇内容 | 2278人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1781298, encodeId=c85b1e8129814, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=美国ASGCT ：Cell Medica公布其细胞疗法CAR-NKT的临床前数据, objectType=article, longId=165510, objectId=599716551027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=599716551027, replyNumber=0, likeNumber=71, createdTime=2019-10-31, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=599716551027, moduleTitle=美国ASGCT ：Cell Medica公布其细胞疗法CAR-NKT的临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=599716551027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781306, encodeId=94571e8130632, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat biotech：超级CAR-T细胞让肿瘤完全消失！, objectType=article, longId=175135, objectId=e8321e51356f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8321e51356f, replyNumber=0, likeNumber=55, createdTime=2019-11-26, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8321e51356f, moduleTitle=Nat biotech：超级CAR-T细胞让肿瘤完全消失！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8321e51356f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781288, encodeId=17ca1e8128850, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Autolus的下一代CAR-T细胞疗法更加安全有效, objectType=article, longId=163641, objectId=23b816364145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23b816364145, replyNumber=0, likeNumber=57, createdTime=2020-01-22, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23b816364145, moduleTitle=Autolus的下一代CAR-T细胞疗法更加安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23b816364145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781259, encodeId=f34d1e81259f7, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=2018 CSCO | 朱军教授：全方位解读CAR-T产品在复发难治性淋巴瘤中的应用现状及前景, objectType=article, longId=149483, objectId=898214948345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898214948345, replyNumber=0, likeNumber=46, createdTime=2019-08-15, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898214948345, moduleTitle=2018 CSCO | 朱军教授：全方位解读CAR-T产品在复发难治性淋巴瘤中的应用现状及前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898214948345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781257, encodeId=0e5e1e8125787, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=诺华CAR-T细胞疗法Kymriah获得加拿大批准上市, objectType=article, longId=148598, objectId=6a66148598f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a66148598f0, replyNumber=0, likeNumber=97, createdTime=2019-02-12, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a66148598f0, moduleTitle=诺华CAR-T细胞疗法Kymriah获得加拿大批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a66148598f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781280, encodeId=d5e51e812800b, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=斯丹赛CAR-T新药ICT19G1获临床试验批件, objectType=article, longId=160919, objectId=f57a160919de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f57a160919de, replyNumber=0, likeNumber=73, createdTime=2019-08-03, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f57a160919de, moduleTitle=斯丹赛CAR-T新药ICT19G1获临床试验批件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f57a160919de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781289, encodeId=ce8d1e81289ec, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=强生CAR-T疗法JNJ-68284528获得了EMA的PRIME认证, objectType=article, longId=163718, objectId=c32e163e1867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c32e163e1867, replyNumber=0, likeNumber=65, createdTime=2019-09-27, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c32e163e1867, moduleTitle=强生CAR-T疗法JNJ-68284528获得了EMA的PRIME认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c32e163e1867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781299, encodeId=86841e8129986, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药, objectType=article, longId=165942, objectId=8c7e165942ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c7e165942ca, replyNumber=0, likeNumber=75, createdTime=2019-10-25, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c7e165942ca, moduleTitle=MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c7e165942ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781276, encodeId=b5831e8127683, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature：阻断CAR-T“杀人风暴”！大牛团队揭示致命性细胞因子风暴缘起，现有高血压药物或可预防, objectType=article, longId=156557, objectId=edc315655e08, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edc315655e08, replyNumber=0, likeNumber=83, createdTime=2019-05-18, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edc315655e08, moduleTitle=Nature：阻断CAR-T“杀人风暴”！大牛团队揭示致命性细胞因子风暴缘起，现有高血压药物或可预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edc315655e08)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781287, encodeId=6bc21e812873d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=《自然》重磅：破解CAR-T疗法缺陷，这种作用是关键！, objectType=article, longId=163497, objectId=e20816349e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e20816349e5b, replyNumber=0, likeNumber=50, createdTime=2019-09-19, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e20816349e5b, moduleTitle=《自然》重磅：破解CAR-T疗法缺陷，这种作用是关键！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e20816349e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781260, encodeId=f7cc1e81260a1, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位, objectType=article, longId=149577, objectId=a4e21495e77d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4e21495e77d, replyNumber=0, likeNumber=62, createdTime=2019-08-15, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4e21495e77d, moduleTitle=【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4e21495e77d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781254, encodeId=cab51e812545a, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Biothechnol：装上了迷你版PD-1抗体的CAR-T细胞，对抗实体瘤如鱼得水, objectType=article, longId=146695, objectId=ffc91466958d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffc91466958d, replyNumber=0, likeNumber=57, createdTime=2019-07-24, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffc91466958d, moduleTitle=Nat Biothechnol：装上了迷你版PD-1抗体的CAR-T细胞，对抗实体瘤如鱼得水, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffc91466958d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781301, encodeId=867a1e81301a7, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Blood杂志发表中和GM-CSF，解决CAR-T诱导神经毒性的潜力, objectType=article, longId=166330, objectId=2578166330b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2578166330b4, replyNumber=0, likeNumber=69, createdTime=2019-08-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2578166330b4, moduleTitle=Blood杂志发表中和GM-CSF，解决CAR-T诱导神经毒性的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2578166330b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781271, encodeId=1d261e812712d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=周剑峰教授：CAR-T治疗在难治恶性血液病中的临床进展, objectType=article, longId=155728, objectId=a849155e285a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a849155e285a, replyNumber=0, likeNumber=80, createdTime=2019-08-05, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a849155e285a, moduleTitle=周剑峰教授：CAR-T治疗在难治恶性血液病中的临床进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a849155e285a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781292, encodeId=e1cc1e81292bf, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=国内首家非病毒载体CAR-T细胞治疗产品获批临床, objectType=article, longId=164209, objectId=53ae164209ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53ae164209ad, replyNumber=0, likeNumber=82, createdTime=2019-10-04, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53ae164209ad, moduleTitle=国内首家非病毒载体CAR-T细胞治疗产品获批临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53ae164209ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781243, encodeId=e5c01e8124373, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Cell Stem Cell：比CAR-T更安全！CAR-NK疗法初显成效, objectType=article, longId=142320, objectId=7aaf14232089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7aaf14232089, replyNumber=0, likeNumber=70, createdTime=2018-10-23, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7aaf14232089, moduleTitle=Cell Stem Cell：比CAR-T更安全！CAR-NK疗法初显成效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7aaf14232089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781291, encodeId=1aa71e81291eb, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T细胞疗法公司Autolus计划后续融资1亿美元, objectType=article, longId=164173, objectId=17f41641e3ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17f41641e3ff, replyNumber=0, likeNumber=60, createdTime=2019-04-17, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17f41641e3ff, moduleTitle=CAR-T细胞疗法公司Autolus计划后续融资1亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17f41641e3ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781264, encodeId=7e241e8126481, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T之后，CAR-巨噬细胞粉墨登场，又成为下一代抗肿瘤明星?, objectType=article, longId=152286, objectId=68da1522864c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68da1522864c, replyNumber=0, likeNumber=75, createdTime=2018-12-26, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68da1522864c, moduleTitle=CAR-T之后，CAR-巨噬细胞粉墨登场，又成为下一代抗肿瘤明星?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68da1522864c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781297, encodeId=da4a1e81297ec, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Autolus双靶头CAR-T疗法AUTO3治疗急性淋巴细胞白血病，获得FDA授予的孤儿药物指定, objectType=article, longId=164953, objectId=996316495364, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=996316495364, replyNumber=0, likeNumber=81, createdTime=2020-03-07, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=996316495364, moduleTitle=Autolus双靶头CAR-T疗法AUTO3治疗急性淋巴细胞白血病，获得FDA授予的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=996316495364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781241, encodeId=100c1e81241c4, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=对抗恶性淋巴瘤 CAR-T技术表现不俗, objectType=article, longId=140834, objectId=c15e140834a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c15e140834a7, replyNumber=0, likeNumber=77, createdTime=2018-06-21, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c15e140834a7, moduleTitle=对抗恶性淋巴瘤 CAR-T技术表现不俗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c15e140834a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAR-

2020-05-29

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

美国ASGCT ：Cell Medica公布其细胞疗法CAR-NKT的临床前数据

2019-10-31

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat biotech：超级CAR-T细胞让肿瘤完全消失！

2019-11-26

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

Autolus的下一代CAR-T细胞疗法更加安全有效

2020-01-22

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

2018 CSCO | 朱军教授：全方位解读CAR-T产品在复发难治性淋巴瘤中的应用现状及前景

2019-08-15

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

诺华CAR-T细胞疗法Kymriah获得加拿大批准上市

2019-02-12

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

斯丹赛CAR-T新药ICT19G1获临床试验批件

2019-08-03

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

强生CAR-T疗法JNJ-68284528获得了EMA的PRIME认证

2019-09-27

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药

2019-10-25

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

Nature：阻断CAR-T“杀人风暴”！大牛团队揭示致命性细胞因子风暴缘起，现有高血压药物或可预防

2019-05-18

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

《自然》重磅：破解CAR-T疗法缺陷，这种作用是关键！

2019-09-19

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位

2019-08-15

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

Nat Biothechnol：装上了迷你版PD-1抗体的CAR-T细胞，对抗实体瘤如鱼得水

2019-07-24

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Blood杂志发表中和GM-CSF，解决CAR-T诱导神经毒性的潜力

2019-08-11

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

周剑峰教授：CAR-T治疗在难治恶性血液病中的临床进展

2019-08-05

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

国内首家非病毒载体CAR-T细胞治疗产品获批临床

2019-10-04

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

Cell Stem Cell：比CAR-T更安全！CAR-NK疗法初显成效

2018-10-23

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T细胞疗法公司Autolus计划后续融资1亿美元

2019-04-17

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T之后，CAR-巨噬细胞粉墨登场，又成为下一代抗肿瘤明星?

2018-12-26

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

Autolus双靶头CAR-T疗法AUTO3治疗急性淋巴细胞白血病，获得FDA授予的孤儿药物指定

2020-03-07

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

对抗恶性淋巴瘤 CAR-T技术表现不俗

2018-06-21

科室
- - 订阅+
  - 更多科室
工具
服务